Author

Ana Gutiérrez-Casbas

PREVALENCE OF UNDIAGNOSED INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHRITIS: EISER STUDY
PREVALENCE OF UNDIAGNOSED INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHRITIS: EISER STUDY

Ana Gutiérrez-Casbas  et al.

OVEREXPRESSION OF MIR-376A-3P IN CIRCULATING EXOSOMES IN PERIPHERAL BLOOD OF PATIENTS WITH CROHN'S DISEASE
OVEREXPRESSION OF MIR-376A-3P IN CIRCULATING EXOSOMES IN PERIPHERAL BLOOD OF PATIENTS WITH CROHN'S DISEASE

Ana Gutiérrez-Casbas  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Ana Gutiérrez-Casbas  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Ana Gutiérrez-Casbas  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Ana Gutiérrez-Casbas  et al.

THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL
THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL

Ana Gutiérrez-Casbas  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Ana Gutiérrez-Casbas  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Ana Gutiérrez-Casbas  et al.

REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY
REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY

Ana Gutiérrez-Casbas  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Ana Gutiérrez-Casbas  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Ana Gutiérrez-Casbas  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Ana Gutiérrez-Casbas  et al.

THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU
THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU

Ana Gutiérrez-Casbas  et al.

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

Ana Gutiérrez-Casbas  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Ana Gutiérrez-Casbas  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Ana Gutiérrez-Casbas  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

Ana Gutiérrez-Casbas  et al.

Item 1 - 17 / 17
1